AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its earnings results on Tuesday. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04, FiscalAI reports. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics delivered a solid FY2026, with revenue up 9.4% to $320.2 million and MedTech revenue up 18.4%, showing continued mix shift toward higher-growth businesses.
• Auryon remained a standout, posting its 20th consecutive quarter of double-digit growth and benefiting from share gains across hospital and office-based lab settings, plus international adoption.
• NanoKnife posted exceptional momentum, with full-year revenue up 35.2% and a record fourth quarter driven by prostate procedures, supported by better clinical data and improving reimbursement coverage.
• Management said mechanical thrombectomy remains a key growth engine, but near-term results were uneven; AlphaVac grew strongly while AngioVac declined in the quarter, and the company is making commercial changes to improve execution.
• Profitability and cash generation improved despite tariffs, with FY2026 adjusted EBITDA rising to $13.2 million, gross margin at 54.6%, and the company ending the year with $53.9 million in cash and no debt. Management guided FY2027 revenue to $336 million-$341 million and expects MedTech growth of 12%-15%.

AngioDynamics Trading Up 1.8%

Shares of NASDAQ ANGO opened at $13.00 on Wednesday. The firm has a market capitalization of $537.16 million, a P/E ratio of -17.33 and a beta of 0.34. The firm’s 50-day moving average price is $12.07 and its 200-day moving average price is $11.32. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ANGO. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Canaccord Genuity Group lowered their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted record fiscal Q4 and full-year 2026 results, highlighting strong execution and med-tech growth. AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.07 per share versus a consensus loss of $0.11, while revenue of $86.61 million beat estimates of $80.24 million. AngioDynamics earnings report and conference call
• Positive Sentiment: Fiscal 2027 revenue guidance of $336 million to $341 million came in above Wall Street expectations, signaling management confidence in continued growth. AngioDynamics posts record Q4 and fiscal 2026 results
• Neutral Sentiment: Analysts’ price targets were revised higher, reflecting improved sentiment after the earnings release. Brokerages Set AngioDynamics, Inc. (NASDAQ:ANGO) PT at $18.67
• Negative Sentiment: Despite the earnings beat, AngioDynamics still expects a FY 2027 EPS loss, so profitability remains a work in progress. AngioDynamics posts record Q4 and fiscal 2026 results

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC bought a new stake in shares of AngioDynamics during the fourth quarter worth about $139,000. Federated Hermes Inc. bought a new position in AngioDynamics in the 4th quarter valued at about $149,000. Cerity Partners LLC boosted its stake in AngioDynamics by 24.5% during the 4th quarter. Cerity Partners LLC now owns 14,310 shares of the medical instruments supplier’s stock valued at $184,000 after purchasing an additional 2,813 shares during the last quarter. State of Wyoming increased its holdings in AngioDynamics by 140.1% during the 4th quarter. State of Wyoming now owns 11,402 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 6,653 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new position in AngioDynamics during the 3rd quarter worth $118,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.